Should diverse representation in UK clinical trials be mandatory?
In the US, FDA guidance states that trials should recruit patients that represent the population that has the burden of disease in the real world. We believe this should be mandatory policy for all clinical trials in the UK.
Recently, coronavirus has bought to light not only the disproportionate impact that conditions can have on certain groups, but that these groups have not been represented in the trials to find a treatment or a vaccine.
We’re bringing together representatives from Parliament, national bodies, and industry to discuss why it isn’t policy now, what needs to be done to make it policy, and what the impact of this would be on industry, researchers, science and society.
MP and Shadow Minster for Science, Research and Digital
CEO Innovative Trials
CEO, COUCH Health and Demand Diversity
Chief Officer at Caribbean and African Health Network
Head of Sales, BioPharma at Source Bioscience
To sign up for the panel discussion due to take place:
Tuesday 10th November
12.30–14.00 GMT / 07:30–09:00 EST
Please fill out your details and you will receive a calendar invite shortly afterwards.